The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1614
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
An EUA for Casirivimab and Imdevimab for COVID-19
The FDA has issued an Emergency Use Authorization (EUA) for Regeneron's investigational monoclonal antibodies casirivimab (REGN10933) and imdevimab (REGN10987) to be administered together by IV infusion for treatment of mild to moderate COVID-19 in adults and pediatric patients (≥12 years old and weigh ≥40 kg) who are at high risk of progressing to severe COVID-19 and/or hospitalization (see Table 1). Bamlanivimab (LY-CoV555; Lilly), another monoclonal antibody, received an EUA for the same indication on November 9, 2020. ... more
     
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1614
 Downloadable, electronic issue - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian